Supplementary Figure S2 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas | Synapse
July 15, 2025
Supplementary Figure S2 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
Key Points
MAIN FINDING: The trial investigated the combination of doxorubicin with zalifrelimab and balstilimab.
KEY EVIDENCE: Selected patients showed responses in cross-sectional imaging after receiving the combined therapy.
APPROACH: A single-arm Phase 2 trial enrolled patients with advanced metastatic soft tissue sarcomas.
SIGNIFICANCE: The study highlights the potential benefits of combining immunotherapy with chemotherapy in treating sarcomas.
Abstract
Figure S2. Representative cross-sectional imaging for selected responding patients.